Company Overview
About Atomic AI
Atomic AI is a biotechnology company founded in 2021 and headquartered in San Francisco, California, at the intersection of artificial intelligence and RNA biology. The company was co-founded by Raphael Townshend, a key contributor to machine learning methods for molecular structure prediction including work related to AlphaFold, reflecting the founding team's deep expertise in applying AI to three-dimensional molecular structure. Atomic AI's platform combines machine learning with structural biology to understand and predict RNA structure and RNA-protein interactions — a capability central to designing drugs that target RNA molecules rather than proteins.
Business Model & Competitive Advantage
RNA therapeutics represents a major frontier in drug discovery: most drugs historically target proteins, but RNA molecules (including mRNA, non-coding RNAs, and regulatory RNAs) control gene expression and are implicated in diseases ranging from cancer to neurological conditions to viral infections. The challenge is that RNA structure is highly dynamic and difficult to characterize experimentally, making rational drug design against RNA targets historically difficult. Atomic AI's ATOM-1 model — a large-scale AI model for RNA structure prediction and interaction modeling — aims to provide the structural intelligence needed to identify druggable RNA targets and design small molecules or oligonucleotide therapeutics that modulate RNA function.
Competitive Landscape 2025–2026
The company raised a $35 million Series A in 2022 from investors including Salesforce Ventures and other institutional backers, providing capital to advance its platform and begin building a drug pipeline. Atomic AI operates in a space that is gaining substantial attention following the clinical success of RNA-based therapeutics (mRNA vaccines, siRNA drugs like inclisiran) and the emergence of sophisticated AI tools for molecular structure prediction. The company competes and collaborates in a landscape that includes AI drug discovery pioneers (Recursion, Schrodinger, Insilico Medicine) as well as RNA-focused biotechs (Arrowhead Pharmaceuticals, Alnylam, PTC Therapeutics).
Key Differentiators
Emerging Innovator
Atomic AI is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Atomic AI with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Atomic AI? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Atomic AI Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Atomic AI vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →